Pharmacyclics (PCYC) yesterday announced 2Q14 results, posting EPS of ($0.49) and revenue of $113.
Yesterday, the FDA granted full approval to Pharmacyclics’ (PCYC) for Imbruvica for both treatment naive del17p (poor cytogenetics) CLL patients and all CLL …
The FDA granted full approval today to Pharmacyclics’ (PCYC) Imbruvica to treat Chronic Lymphocytic Leukemia (CLL) and as front-line therapy to treat CLL patients with …
In a research note published today, Wedbush analyst David Nierengarten reiterated an Outperform rating on Pharmacyclics (PCYC), with a $225 price target, following today’s news that PCYC and Janssen …
